Articles tagged with Cell Therapies
Researchers found correlations between MIF and DDT levels with patient survival outcomes in melanoma patients. Higher CD74:MIF and CD74:DDT levels were associated with improved survival and enrichment of inflammatory markers.
A recent study found that 'gene misbehaviour' is a common phenomenon in the healthy human population, with over half of inactive genes showing misexpression. The researchers used advanced techniques to analyze blood samples from 4,568 healthy individuals and identified mechanisms behind these gene activity errors.
Researchers at the Mayo Clinic Comprehensive Cancer Center discovered a new treatment approach that improved survival rates for patients with B-cell precursor leukemia by nearly 60%. The study found that adding blinatumomab to chemotherapy reduced the risk of leukemia recurrence and death.
Scientists improve stability and bioavailability of mRNA nanocarriers using triphenylphosphonium, leading to increased protein production in tumor tissues. The TPP-based system also shows higher mRNA levels in blood after 30 minutes compared to amine-based micelles.
A preclinical study suggests that knocking out CD5 on CAR T cells boosts their anti-tumor efficacy against various cancers, including solid tumors. The researchers found that CD5 deletion enhances the function of CAR T cells by reining in immune responses and increasing cancer-cell-killing activity.
A phase II clinical trial found that combining sEphB4-HSA with pembrolizumab improved outcomes in HPV-negative, EphrinB2-positive head and neck squamous cell carcinoma patients. The combination showed a favorable toxicity profile and activity, particularly among those with HNSCC.
Researchers found that subretinal adeno-associated virus 8 injections trigger proinflammatory T-cell responses, but co-injection of immunodominant peptides can modulate the immune system. This study suggests a new approach to AAV gene therapy for retinal diseases.
The FDA approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy, marks a major advancement in personalized cancer treatment. Moffitt researchers are expanding this therapeutic approach to treat other solid tumor cancer types, such as lung, sarcoma, cervical and bladder.
Researchers created a new cell model to study the effects of senescence on lung fibroblasts. Senescent alveolar epithelial cells triggered fibrotic activation in lung fibroblasts, which was attenuated by senolytic therapy.
Researchers explore various immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, as promising treatments for hepatocellular carcinoma. The review aims to overcome current limitations of targeted therapies by regulating the body's immune systems.
Researchers at Memorial Sloan Kettering Cancer Center found that the spatial arrangement of three immune cells - dendritic cell, cytotoxic T cell, and helper T cell - is crucial for effective killing of cancer cells. This discovery has immediate therapeutic implications for immunotherapy treatments.
A new CAR-T cell therapy targeting CD22 has shown significant improvement in patients with large B-cell lymphoma, with over half experiencing a complete response. The therapy, which targets a different protein on the surface of cancer cells, has improved outcomes for patients who have failed previous treatments.
Researchers describe redundant innate immune pathways triggered by AAV vectors, including sensing of viral genome and cytoplasmic DNA sensors. The study highlights the need to understand complex biologic mechanisms underlying adverse reactions to AAV vectors in human gene therapy trials.
A new immune cell therapy has been shown to delay ALS onset and extend survival in mice, as well as reduce inflammation in an individual with the disease. In a phase I clinical trial, the therapy is now set to be tested on humans.
Researchers identified a population of stem-like cells that initiates and maintains Group 3 medulloblastoma (Gr3-MB) in the developing brain. Eliminating these cells led to tumor shrinkage in preclinical models, suggesting a novel approach for treating children with Gr3-MB.
Researchers at the University of Notre Dame have developed a wireless LED device that can be implanted to treat deep-seated cancers. The device, combined with a light-sensitive dye, destroys cancer cells and triggers an immune response against them.
Researchers discuss the critical role of the retinal pigmented epithelium in human vision and its susceptibility to aging. The study highlights the importance of understanding molecular and cellular mechanisms driving age-related pathological changes in vision decline.
A systematic review and meta-analysis of CAR T cell therapy reveals that infections are the main driver of non-relapse mortality in patients. The study analyzed reports from over 7,600 patients across 18 clinical trials and found that infections accounted for half of all reported non-relapse related deaths.
LNP-mRNA therapy faces challenges like targeting, quality control, and safety concerns. Researchers are optimizing dosage, addressing CMC requirements, and enhancing targeting efficiency to improve therapeutic outcomes.
Researchers have identified a novel type of T cell that can recognize and respond to multiple bacterial strains in the gut. This breakthrough finding has significant implications for treating diseases such as cancer and inflammatory bowel disease. The discovery was made by Kazuki Nagashima, winner of the NOSTER & Science Microbiome Prize.
Immunotherapies have revolutionized HCC treatment by enhancing the immune system's ability to recognize and destroy cancer cells. Key approaches include checkpoint inhibitors, targeted therapies, and advanced cellular immunotherapies.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
Researchers identify key proteins and signaling pathways for personalized treatment, enabling early detection of aggressive tumors. The study provides a crucial resource for developing new therapies and tests to guide treatment.
Researchers at Howard University have identified a new therapeutic strategy to combat prostate cancer by depleting amino acids. This depletion induces oxidative stress and DNA damage in cancer cells, making them more susceptible to treatment with DNA repair-targeted and immune checkpoint blockade therapies.
A new biomarker has been discovered that can help predict which patients with clear cell renal cancer are at higher risk of recurrence. The 15-gene signature was found to be independently associated with worse disease-free survival and disease-specific survival in two large validation datasets.
Researchers at Georgia Tech have developed a method to improve adoptive T-cell therapy using nanowires to deliver therapeutic miRNA to naïve T-cells. This approach retains the cells' naïve state, making them more effective disease fighters when infused back into patients.
Researchers at MD Anderson Cancer Center have identified a small molecule compound that restores physiological levels of telomerase reverse transcriptase (TERT), reducing cellular senescence and tissue inflammation. TERT restoration also spurred new neuron formation with improved memory and enhanced neuromuscular function.
Recent research reveals that targeting senescent cells as the cause of aging is not accurate. Instead, these cells have positive health impacts and may pose risks if targeted therapeutically.
Researchers at EPFL have published an open-source project Tabulae Paralytica, providing a comprehensive understanding of spinal cord injury biology. The study identifies specific neurons and genes involved in recovery and proposes a successful gene therapy derived from its discoveries.
Researchers found a link between gut microbiota and Parkinson's disease, revealing reduced B vitamins and intestinal barrier issues. Treatment with B vitamins could alleviate PD symptoms and slow disease progression.
Researchers at Francis Crick Institute develop a new genetic therapy that silences mutated NRAS gene in cells with congenital melanocytic naevus syndrome (CMN), potentially reversing debilitating giant moles. The treatment has shown promising results in mice and could be used to reduce cancer risk in affected children and adults.
Scientists at St. Jude Children's Research Hospital discovered that NLRC5 plays a crucial role as an innate immune sensor, triggering PANoptotic cell death. The findings suggest that targeting NLRC5 could lead to therapeutic development for infections, inflammatory diseases, and aging.
Researchers developed an ex vivo gene-editing protocol to treat hereditary tyrosinemia type 1 using liver cell therapy. The study showed robust engraftment and expansion of transplanted gene-edited hepatocytes in recipient mice, correcting disease indicators such as normalized tyrosine, phenylalanine levels.
Researchers at Wyss Institute develop subcutaneous scaffolds to restimulate CAR-T cells, increasing therapeutic efficacy in mice with aggressive blood tumors. The biomaterials increase CAR-T cell numbers and steer differentiation into tumor-killing T cells.
A new detailed analysis of a patient's second cancer after receiving CAR-T therapy provides valuable guidance for clinicians. The study reveals that CAR-T related second cancers can occur, often with lymphomas, and highlights the need for early detection and management.
The study highlights the potential of omics research and AI tools to disentangle the molecular drivers of Alzheimer’s disease. Key findings include the identification of novel biomarkers for early detection and therapeutic targets, as well as the exploration of genetic factors contributing to AD risk and progression.
Researchers identify UBE2J1's role in degrading the androgen receptor, a key player in prostate cancer progression. The study suggests targeting this ubiquitination machinery may help overcome antiandrogen resistance in cancer therapy.
A new study found that combining histone deacetylase inhibitors, poly (ADP ribose) polymerase inhibitors, and decitabine resulted in synergistic cytotoxicity in all cell lines tested. This combination impaired DNA repair pathways and altered epigenetic regulation of gene expression.
A new 'armored' form of CAR T cell therapy, developed by University of Pennsylvania researchers, has shown significant responses in patients whose cancers don't respond to current CAR T cell therapies. The three-day manufacturing process also shortens treatment time for aggressive, fast-growing cancers.
Ivonescimab plus chemotherapy significantly improved progression-free survival (7.1 vs 4.8 months) compared to chemotherapy alone in TKI-treated non-small cell lung cancer patients. This treatment may offer a new option for patients with EGFR variant and limited treatment options.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
Researchers discover novel suppressive role of Ctdnep1 in osteoclast differentiation and bone resorption, suggesting potential therapeutic targets for treating excessive bone loss. The study reveals that Ctdnep1 functions as a brake on osteoclast cell differentiation.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
Researchers at the University of Houston have identified a subset of T cells called CD8-fit that show high motility and serial killing capabilities in patients with clinical responses. These cells were discovered using a patented approach called TIMING, which evaluates cell behavior and movement to identify potential cancer-killing cells.
Researchers review Silibinin's efficacy in managing inflammation, a key factor in tumour development and aging. The molecule may reduce drug-related toxicity and increase therapeutic potential in integrated cancer therapies.
A study published in Radiology found that low-level light therapy increased resting-state functional connectivity in patients with moderate traumatic brain injuries. The treatment showed improved brain connectivity within the first two weeks, but its long-term effects are still unclear.
Researchers at USask have discovered a new peptide that lowers lipid accumulation in human liver cells, offering new avenues for treating metabolic diseases. The finding is hopeful news as there's a lack of new therapies available for these diseases.
The study reveals that FLVCR1 and FLVCR2 transport choline and ethanolamine across cellular membranes, supporting cell growth and stability. This discovery contributes to understanding rare diseases and developing new therapies for patients suffering from severe neurological and muscular disorders.
Researchers from Penn Medicine's Abramson Cancer Center and Perelman School of Medicine will present results from clinical trials for esophageal cancer, CAR T cell therapy, and ovarian cancer. The meeting will feature more than 200 sessions on AI in cancer care.
Scientists have discovered the transporters responsible for delivering essential nutrients choline and ethanolamine to human cells. The study sheds light on the atomic structure of these transporters and their role in distributing micronutrients throughout the body, providing a foundation for new therapeutic approaches.
A novel therapy has been developed to reprogram macrophage immune cells, shifting their balance toward antitumor activity. The treatment, JHU083, blocks the use of glutamine in tumors, reducing growth and triggering cell death. It also boosts immune-activating macrophages, recruiting tumor-killing T-cells and natural killer cells.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
A Cleveland Clinic-led team of scientists discovered that protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The interaction between VISTA and a newly discovered inhibitory receptor LRIG1 suppresses T cell replication, survival, and function.
Researchers discuss the benefits of CAR-T therapy in treating B-cell lineage acute lymphoblastic leukemia (B-ALL) in children. The therapy, tisagenlecleucel, has shown promising results and is now priced at $508,250, a more manageable cost compared to other gene therapies.
A recent study reveals that a cellular process called transfer Ribonucleic acid (tRNA) modification influences the malaria parasite’s ability to develop resistance. This breakthrough discovery could help researchers develop new drugs to combat resistance and better tools for studying RNA modifications.
A new study shows that gene therapy delivered by nanocarriers can repair damaged discs and reduce signs of back pain in mice. The treatment, which uses naturally derived nanocarriers to deliver genetic material for a protein key to tissue development, restored structural integrity and function to degenerated discs.
A new Dartmouth-led study has provided new insights into the therapeutic potential of bacteriophage therapy for treating diseases like cystic fibrosis. Researchers found that respiratory epithelial cells sense and respond to therapeutic phages, and interactions between phages and epithelial cells are heterogenous in nature.
University of Minnesota researchers found that immunotherapy improves CD8+ T-cell responses in older mice, reducing mortality from infections. The treatment, PD1 blockade, enhances the ability of T cells to kill harmful cells infected with a virus.
Researchers discuss therapeutic opportunities for hypermutated urothelial carcinomas that are resistant to immunotherapy, including the potential of targeted therapies. High TMB is associated with defects in mismatch repair proteins and can lead to increased sensitivity to cancer treatments.
Dana-Farber researchers discovered a molecular complex called PI3Kgamma that supports the survival of certain leukemia cells. The team found that eganelisib, an existing medicine, can inhibit this complex and has shown promise in animal models and clinical trials.